Aids

Aids

艾滋病

  • 2区 中科院分区
  • Q2 JCR分区

期刊简介

《Aids》是由Lippincott Williams and Wilkins Ltd.出版社于1987年创办的英文国际期刊(ISSN: 0269-9370,E-ISSN: 1473-5571),该期刊长期致力于免疫学领域的创新研究,主要研究方向为医学-病毒学。作为SCIE收录期刊(JCR分区 Q2,中科院 2区),本刊采用OA未开放获取模式(OA占比0.1098...%),以发表免疫学领域等方向的原创性研究为核心(研究类文章占比95.73%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在211篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Aids审稿周期约为 约1月 。该刊近年未被列入国际预警名单,年发文量约211篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 211 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
2区
IMMUNOLOGY 免疫学 INFECTIOUS DISEASES 传染病学 VIROLOGY 病毒学
2区 2区 2区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
2区
IMMUNOLOGY 免疫学 INFECTIOUS DISEASES 传染病学 VIROLOGY 病毒学
2区 2区 2区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q3 93 / 181

48.9%

学科:INFECTIOUS DISEASES SCIE Q2 47 / 132

64.8%

学科:VIROLOGY SCIE Q3 21 / 41

50%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q2 88 / 181

51.66%

学科:INFECTIOUS DISEASES SCIE Q2 57 / 132

57.2%

学科:VIROLOGY SCIE Q2 18 / 41

57.32%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:5.9 SJR:1.401 SNIP:0.879
学科类别 分区 排名 百分位
大类:Medicine 小类:Infectious Diseases Q2 114 / 344

67%

大类:Medicine 小类:Immunology and Allergy Q2 102 / 233

56%

大类:Medicine 小类:Immunology Q3 122 / 236

48%

期刊发文

  • Economic evaluation of improving HIV self-testing among MSM in China using a crowdsourced intervention: a cost-effectiveness analysis

    Author: Ong, Jason J. J.; Booton, Ross D. D.; Tucker, Joseph D. D.; Tang, Weiming; Vickerman, Peter; Zhang, Lei; Mitchell, Kate M. M.

    Journal: AIDS. 2023; Vol. 37, Issue 4, pp. 671-678. DOI: 10.1097/QAD.0000000000003457

  • Factors associated with reduced function and quality of life among adult people with HIV with depression and substance use in the Asia-Pacific region

    Author: Rajasuriar, Reena; Chong, Meng Li; Ross, Jeremy; Jiamsakul, Awachana; Avihingsanon, Anchalee; Lee, Man Po; Ditangco, Rossana; Choi, Jun Yong; Gatechompol, Sivaporn; Chan, Iris; Melgar, Maria Isabel Echanis; Kim, Jung Ho H.; Sohn, Annette; Law, Matthew

    Journal: AIDS. 2023; Vol. 37, Issue 5, pp. 823-835. DOI: 10.1097/QAD.0000000000003474

  • Longitudinal characterization of circulating extracellular vesicles and small RNA during simian immunodeficiency virus infection and antiretroviral therapy

    Author: Huang, Yiyao; Liao, Zhaohao; Dang, Phuong; Queen, Suzanne; Abreu, Celina Monteiro; Gololobova, Olesia; Zheng, Lei; Witwer, Kenneth W.

    Journal: AIDS. 2023; Vol. 37, Issue 5, pp. 733-744. DOI: 10.1097/QAD.0000000000003487

  • Structural and functional characterization of HIV-1 cell fusion inhibitor T20.

    Author: Zhang X1,2, Ding X1, Zhu Y1, Chong H1, Cui S1, He J2, Wang X3, He Y1,2.

    Journal: AIDS. 2019 Jan 27;33(1):1-11. doi: 10.1097/QAD.0000000000001979.

  • Rapid CD4+ T-cell decline is associated with coreceptor switch among MSM primarily infected with HIV-1 CRF01_AE in Northeast China.

    Author: Cui H1,2,3, Geng W1,2,3, Sun H1,2,3, Han X1,2,3, An M1,2,3, Jiang Y1,2,3, Zhang Z1,2,3, Chen Z4, Xu J1,2,3, Hu Q1,2,3, Zhao B1,2,3, Zhou B1,2,3, Shang H1,2,3.

    Journal: AIDS. 2019 Jan 27;33(1):13-22. doi: 10.1097/QAD.0000000000001981.

  • Increased influenza-specific antibody avidity in HIV-infected women compared with HIV-infected men on antiretroviral therapy.

    Author: Luo Z1, Ogunrinde E1, Li M1, Zhang L2, Martin L3, Zhou Z1, Hu Z1,4, Zhang T1,5, Li Z1,6, Zhang J1,7, Su B6, Zhang T6, Wu H6, Ma L8, Liao G8, Eckard AR3,9, Westerink MAJ1,3, Heath SL10, Jiang W1,3.

    Journal: AIDS. 2019 Jan 27;33(1):33-44. doi: 10.1097/QAD.0000000000002022.

  • Vedolizumab-mediated integrin α4β7 blockade does not control HIV-1SF162 rebound after cART interruption in humanized mice.

    Author: Ling L1,2, Wu T1, To KKW1, Cheung KW1, Lui KO3, Niu M1, Lam KS1, Wang CC4, Li J3, Wang H2, Yuen KY1, Chen Z1,2.

    Journal: AIDS. 2019 Jan 14. doi: 10.1097/QAD.0000000000002149. [Epub ahead of print]

  • Vedolizumab-mediated integrin α4β7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice.

    Author: Ling L1,2, Wu T1, To KKW1, Cheung KW1, Lui KOL3, Niu M1, Lam KS1, Wang CC4, Li J3, Wang H2, Yuen KY1, Chen Z1,2.

    Journal: AIDS. 2019 Mar 15;33(4):F1-F12. doi: 10.1097/QAD.0000000000002149.